To date, there is no specific association between PD-L1 expression and the efficacy of anti-PD-1/PD-L1 immunotherapy in colorectal cancer [49, 50], but no data are available for the subset of BRAF mutations. This evidence concerns the gene BRAF and colorectal cancer.